Document is current
Any future updates will be listed below
-
Authors
Alonso-Romero, José Luis
Martínez-García, Jerónimo
Carrillo-Vicente, Raúl
Aramburo, Antonio Fernández
Díez, Angélica Ferrando
Henarejos, Pilar Sánchez
de la Morena Barrio, Pilar
Boix, Ana Puertes
Jiménez, Mª Dolores
Siles, Joaquín Peña
Maestre, José Antonio Parejo
de las Heras-Rubio, Antonio
Carreño, Paula Ruiz
- License Information
-
More Information
Article History
Received: 3 November 2025
Accepted: 7 January 2026
First Online: 20 January 2026
Declarations
:
: A. Fernández Aramburu reported speaker bureau fees from Pfizer, Lilly and Novartis. AHR is an employee of Kern Pharma S.L. P. de la Morena Barrio reported honoraria from Astrazeneca, GSK, Lilly, Clovis Oncology, MSD, Roche; travel support from Roche, Lilly, GSK, MSD, Novartis. A. de las Heras-Rubio is an employee of Kern Pharma, S.L. All other authors declare no potential conflicts of interest.
: Written informed consent was obtained from all participants, and the study was approved by the Ethics Committee (2020–3-2-HCUVA) of the Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.
: Not applicable.
